Therapeutic Approaches to Targeting Androgen Receptor Splice Variants
Cells · 04.01.2024 · 13 (1) · 104
DOI: 10.3390/cells13010104 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 04.01.2024. Verfasst von Violet A Daniels und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Neoplastic Cells, Circulating. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, DOD, NIH.
Abstract (Originalsprache)
Therapeutic options for advanced prostate cancer have vastly expanded over the last decade and will continue to expand in the future. Drugs targeting the androgen receptor (AR) signaling pathway, i.e., androgen receptor targeting agents (ARTAs), remain the mainstream treatments that are increasingly transforming the disease into one that can be controlled for an extended period of time. Prostate cancer is inherently addicted to AR. Under the treatment pressure of ARTA, molecular alterations occur, leading to the clonal expansion of resistant cells in a disease state broadly categorized as castration-resistant prostate cancer (CRPC). One castration resistance mechanism involves AR splice variants (AR-Vs) lacking the ligand-binding domain. Some AR-Vs have been identified as constitutively active, capable of activating AR signaling pathways without androgenic ligands. Among these variants, AR-V7 is the most extensively studied and may be measured non-invasively using validated circulating tumor cell (CTC) tests. In the context of the evolving prostate cancer treatment landscape, novel agents are developed and evaluated for their efficacy in targeting AR-V7. In patients with metastatic CRPC (mCRPC), the availability of the AR-V7 tests will make it possible to determine whether the treatments are effective for CTC AR-V7-positive disease, even though the treatments may not be specifically designed to target AR-V7. In this review, we will first outline the current prostate cancer treatment landscape, followed by an in-depth review of relatively newer prostate cancer therapeutics, focusing on AR-targeting agents under clinical development. These drugs are categorized from the standpoint of their activities against AR-V7 through direct or indirect mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
- Departments of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
ORCID-Profile: Violet A Daniels, Channing J Paller
Förderung
- NCI NIH HHS
- DOD
- NIH
- National Capital Cancer Research Fund
Zitieren
APA
Daniels, V. A., Luo, J., Paller, C. J., & Kanayama, M. (2024). Therapeutic Approaches to Targeting Androgen Receptor Splice Variants. Cells, 13(1), 104. https://doi.org/10.3390/cells13010104
Vancouver
Daniels VA, Luo J, Paller CJ, Kanayama M. Therapeutic Approaches to Targeting Androgen Receptor Splice Variants. Cells. 2024;13(1):104. doi:10.3390/cells13010104
BibTeX
@article{Daniels2024,
author = {Daniels, Violet A and Luo, Jun and Paller, Channing J and Kanayama, Mayuko},
title = {Therapeutic Approaches to Targeting Androgen Receptor Splice Variants},
journal = {Cells},
year = {2024},
volume = {13},
number = {1},
pages = {104},
doi = {10.3390/cells13010104}
}
EUVIMED